Order results by:
| Issue | Title | |
| Vol 8, No 4 (2012) | ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE | Abstract similar documents |
| S. R. Gilyarevskiy, V. A. Orlov, I. M. Kuz'mina, A. G. Larin | ||
| "... Alternative approaches to the use of two component antiplatelet therapy in patients with acute ..." | ||
| Vol 13, No 6 (2017) | CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE | Abstract similar documents |
| A. I. Akhmetova, E. B. Kleimenova, D. A. Sychev, O. V. Parshina, L. P. Yashina | ||
| "... of antiplatelet therapy in patients with acute coronary syndrome (ACS) in routine practice. Material and methods ..." | ||
| Vol 13, No 4 (2017) | PROLONGED DUAL ANTIPLATELET THERAPY AFTER MYOCARDIAL INFARCTION: WHAT THE RESULTS OF THE PEGASUS-TIMI 54 TRIAL SHOW | Abstract similar documents |
| I. S. Yavelov | ||
| "... Prerequisites for the prolonged dual antiplatelet therapy after myocardial infarction are presented ..." | ||
| Vol 18, No 5 (2022) | The Problem of Drug Interactions Between Rosuvastatin and Ticagrelor in the Aspect of the Risk of Rhabdomyolysis: Discussion of the Problem and Description of the Clinical Case | Abstract similar documents |
| O. V. Gaisenok, Yu. M. Chichkov, M. V. Leonova | ||
| "... Background. Combination therapy with two antiplatelet agents (ticagrelor or clopidogrel plus ..." | ||
| Vol 16, No 6 (2020) | Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice? | Abstract similar documents |
| T. M. Uskach, A. S. Tereshchenko | ||
| "... Dual antiplatelet therapy is the most important step in acute coronary syndrome (ACS) treatment ..." | ||
| Vol 7, No 1 (2011) | NEW ANTIPLATELET DRUGS (PART 1) | Abstract similar documents |
| A. B. Sumarokov | ||
| "... antiplatelet drugs are on their way to clinical application — prasugrel, ticagrelor, elinogrel, inhibitors ..." | ||
| Vol 7, No 5 (2011) | NEW ANTIPLATELET DRUGS. PART 2 | Abstract similar documents |
| A. B. Sumarokov | ||
| "... Antiplatelet agents are a necessary component of modern therapy of atherosclerosis ..." | ||
| Vol 15, No 2 (2019) | The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention | Abstract similar documents |
| A. S. Tereshchenko, E. V. Merkulov, A. N. Samko, S. A. Abugov | ||
| "... . In addition to endovascular treatment, dual antiplatelet therapy plays a key role in the treatment ..." | ||
| Vol 14, No 2 (2018) | WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| M. Yu. Gilyarov, Е. V. Konstantinova | ||
| "... as the second component of dual antiplatelet therapy, the possibility of prasugrel or ticagrelor usage should ..." | ||
| Vol 13, No 5 (2017) | INFLUENCE OF SWITCHING OF CLOPIDOGREL TO TICAGRELOR ON THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ST SEGMENT ELEVATION | Abstract similar documents |
| E. V. Tavlueva, A. V. Alekseenko, O. V. Gruzdeva, O. L. Barbarash | ||
| "... Aim. To study the effect of replacing clopidogrel with ticagrelor on endpoints of hospital period ..." | ||
| Vol 14, No 6 (2018) | P2Y12 Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel | Abstract PDF (Eng) similar documents |
| N. M. Vorobyeva | ||
| "... with clopidogrel or ticagrelor was performed, as well as of all 3 P2Y12-receptor inhibitors among themselves ..." | ||
| Vol 7, No 3 (2011) | MODERN ANTIPLATELET THERAPY OF ISCHEMIC HEART DISEASE PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS: DATA FROM EVIDENCE-BASED MEDICINE AND REAL PRACTICE | Abstract similar documents |
| S. Yu. Martsevich, M. L. Ginzburg, A. M. Malysheva, Yu. N. Polyanskaya, T. G. Kheliya, N. P. Kutishenko | ||
| "... the need of dual antiplatelet agents therapy. ..." | ||
| Vol 11, No 4 (2015) | EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME | Abstract similar documents |
| A. V. Rudakova, N. V. Lomakin | ||
| "... the prescription of new antiplatelet drugs, particularly the combination of ticagrelor with aspirin. Aim ..." | ||
| Vol 14, No 2 (2018) | DOCTOR’S ADHERENCE TO RECOMMENDATIONS GOVERNING THE ANTIPLATELET AGENTS USE IN THE CARDIOVASCULAR DISEASES PREVENTION AND TREATMENT | Abstract similar documents |
| N. В. Perepech, A. V. Tregubov | ||
| "... Aim. To study the doctors' opinions on the main aspects of antiplatelet agents use, and to test ..." | ||
| Vol 20, No 3 (2024) | Use of glycoprotein IIb/IIIa inhibitors in myocardial infarction in the Russian Federation, according to the Russian Registry of Acute Myocardial Infarction REGION-IM | Abstract similar documents |
| N. S. Kostritca, R. M. Rabinovich, R. M. Shakhnovich, I. S. Yavelov, R. G. Gulyan, Yu. K. Rytova, S. N. Tereschenko, A. D. Erlikh, D. V. Pevzner | ||
| "... выполнялось чрескожное коронарное вмешательство (ЧКВ), при этом среди пациентов с инфарктом миокарда без ..." | ||
| Vol 13, No 1 (2017) | ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY | Abstract similar documents |
| E. А. Ushkalova, S. K. Zyryanov, E. V. Dumchenko | ||
| "... as first-line drugs for stroke prevention, but in real medical practice antiplatelet drugs are often ..." | ||
| Vol 2, No 3 (2006) | ANTITHROMBOTIC THERAPY OF ISCHEMIC HEART DISEASE: FROM FAST ACTING ANTIAGGREGANTS TO STATINES AND NITRATE OXIDE. IS IT REAL? | Abstract similar documents |
| I. A. Latfullin, A. A. Podolskaya | ||
| "... of action and clinical efficiency of antithrombotic and antiplatelet medicines such as acetylsalicylic acid ..." | ||
| Vol 8, No 2 (2012) | UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE | Abstract similar documents |
| S. Yu. Martsevich, V. P. Voronina, M. L. Ginzburg, N. P. Kutishenko, Yu. N. Polyanskaya, T. G. Kheliya, A. M. Malysheva, S. N. Tolpygina, V. S. Kutuzova, E. A. Gofman, A. D. Deev | ||
| "... Aim. To assess the real rate of dual antiplatelet therapy (DAT, acetylsalicylic acid + clopidogrel ..." | ||
| Vol 5, No 5 (2009) | EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| A. L. Alyavi, R. A. Rakhimov, B. A. Alyavi | ||
| "... and combined antiplatelet therapy (acetylsalicylic acid and clopidogrel). Material and methods. 98 patients ..." | ||
| Vol 13, No 2 (2017) | SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY) | Abstract similar documents |
| S. B. Fitilev, I. I. Shkrebneva, A. V. Vozzhaev, D. A. Dimitrova | ||
| "... recommended for patients with a history of myocardial infarction (antiplatelets – 91.76%, beta-blockers – 83 ..." | ||
| Vol 6, No 4 (2010) | ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY? | Abstract similar documents |
| S. J. Martsevich | ||
| Vol 11, No 2 (2015) | CLINICAL CASE HISTORY OF EPTIFIBATIDE USE DURING CORONARY INTERVENTION IN PATIENT WITH CORONARY FAILURE | Abstract similar documents |
| K. A. Kireev, A. V. Krasnopeev, T. S. Kireeva | ||
| "... antiplatelet drugs (acetylsalicylic acid and clopidogrel) and heparin. There were not any reasons ..." | ||
| Vol 10, No 5 (2014) | DUAL ANTIPLATELET THERAPY IN THE REAL CLINICAL PRACTICE | Abstract similar documents |
| G. N. Guseva, T. V. Pavlova, I. L. Voronova, S. M. Chohlunov | ||
| "... Aim. To evaluate an adequacy of dual antiplatelet therapy (DAPT) in patients with acute coronary ..." | ||
| Vol 9, No 4 (2013) | THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE | Abstract similar documents |
| K. B. Mirzaev, D. A. Sychev, D. A. Andreev, A. B. Prokofiev | ||
| "... is discussed. Approaches to antiplatelet agent choice according to pharmacogenetic CYP2C19 testing, as well ..." | ||
| Vol 9, No 6 (2013) | ANTIPLATELET THERAPY CONTROL: CREDIBILITY GAP OR SEARCH FOR NEW DECISIONS? | Abstract similar documents |
| Yu. I. Grinshtein, A. A. Kosinova, I. Yu. Grinshtein | ||
| "... heart disease after percutaneous coronary intervention and its contribution to antiplatelet therapy ..." | ||
| Vol 15, No 6 (2019) | New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease | Abstract similar documents |
| N. B. Perepech | ||
| "... of patients with chronic IHD are also presented. The main attention is paid to antiplatelet agents ..." | ||
| Vol 16, No 2 (2020) | LIS-3 Acute Coronary Syndrome Registry: Changes in Clinical and Demographic Characteristics and Tactics of Prehospital and Hospital Treatment of Surviving Patients After Acute Coronary Syndrome Over a 4-Year Period | Abstract similar documents |
| S. Yu. Martsevich, A. V. Zagrebelnyy, N. P. Zolotareva, N. P. Kutishenko, Yu. V. Lukina, M. L. Ginzburg, D. A. Startsev, S. V. Blagodatskikh | ||
| "... in angioplasty with stenting were found. Patients before ACS in 2014 received less antiplatelet agents than ..." | ||
| Vol 5, No 6 (2009) | RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID | Abstract similar documents |
| N. F. Puchinyan, N. V. Furman, A. R. Kiselev, Ya. P. Dovgalevsky | ||
| "... Цель. Оценить риск повторных тромботических осложнений у больных острым коронарным синдромом (ОКС ..." | ||
| Vol 13, No 6 (2017) | ASSESSMENT OF CHANGES IN QUALITY OF PREHOSPITAL TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME IN THE LAST FEW YEARS: LIS-1 VS LIS-3 REGISTRIES | Abstract similar documents |
| Yu. V. Semenova, A. V. Zagrebelnyy, N. P. Kutishenko, M. L. Ginzburg, S. Yu. Martsevich | ||
| "... in the LIS-1 registry, more often took antiplatelet drugs (23.2% vs 15.7%, respectively; p<0.01) and statins ..." | ||
| Vol 8, No 1 (2012) | RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION | Abstract similar documents |
| V. A. Sulimov, E. V. Moroz | ||
| "... of cardiovascular complications and activity of platelet aggregation, to assess safety of dual antiplatelet therapy ..." | ||
| Vol 16, No 6 (2020) | Actual Issues of Ischemic and Hemorrhagic Events Risk Management During Antithrombotic Therapy in Patients with Acute Coronary Syndrome | Abstract similar documents |
| R. M. Velieva, T. B. Pecherina, A. S. Vorobiev, V. V. Kashtalap, D. Yu. Sedykh | ||
| "... Today, optimal duration of double antiplatelet (DAPT) and triple antithrombotic therapy (TATT ..." | ||
| Vol 4, No 2 (2008) | ANTIPLATELET THERAPY RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION | Abstract similar documents |
| D. H. Ainetdinova, A. Е. Udovichenko, V. A. Sulimov | ||
| "... of antiplatelet therapy resistance is significantly higher in patients with diabetes mellitus and obesity (р<0 ..." | ||
| Vol 20, No 5 (2024) | Postmyocardial syndrome after myocardial infarction and percutaneous coronary intervention | Abstract similar documents |
| A. A. Klimenko, N. A. Demidova, V. V. Veselkin, T. A. Kirdyashkina, A. A. Chinova, Yu. A. Shandanovina | ||
| "... . Hospital treatment was carried out with colchicine, methylprednisolone, acetylsalicylic acid, ticagrelor ..." | ||
| Vol 10, No 6 (2014) | CHANGES IN PREHOSPITAL PHARMACOTHERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN 2005-2014 ACCORDING TO THE LIS REGISTER | Abstract similar documents |
| S. Y. Martsevich, M. L. Ginzburg, N. P. Kutishenko, A. V. Zagrebelnyy, I. S. Balashov, L. G. Garkina | ||
| "... . The positive changes in the prescription of antiplatelet agents (13.5% in 2005 and 27.4% in 2014), statins (1 ..." | ||
| Vol 15, No 5 (2019) | Prediction of the Possibility of Hemorrhagic Syndrome during Combined Antiplatelet Therapy According to the Krasnodar Region Registry | Abstract similar documents |
| Z. G. Tatarintseva, E. D. Kosmacheva, S. V. Kruchinova, V. A. Akinshina, A. A. Khalafyan | ||
| "... of Cardiology (ESC), patients with coexisting AF and ACS should receive dual antiplatelet therapy ..." | ||
| Vol 14, No 3 (2018) | THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov, N. Yu. Voevodina, S. S. Sharonova | ||
| "... schemes and the preferred doses of statins and antiplatelet agents depending on the localization ..." | ||
| Vol 12, No 4 (2016) | Adherence to attendance at outpatient clinic, quality of prehospital therapy, and direct outcome of acute coronary syndrome: analysis within LIS-3 registry | Abstract similar documents |
| Yu. V. Semenova, N. P. Kutishenko, A. V. Zagebelnyy, A. D. Deev, M. L. Ginzburg, S. Yu. Martsevich | ||
| "... infarction as an outcome of ACS. Taking antiplatelet agents, beta-blockers and long-acting nitrates before ..." | ||
| Vol 12, No 4 (2016) | High residual platelet reactivity during dual antiplatelet therapy, found by optical aggregometry and the rate of atherothrombotic complications after coronary artery stenting in patients with ischemic heart disease in clinical practice | Abstract similar documents |
| N. F. Puchinyan, N. V. Furman, P. V. Dolotovskaya, L. L. Malinova | ||
| "... antiplatelet therapy (DAT) with acetylsalicylic acid (ASA) and clopidogrel by optical aggregometry in patients ..." | ||
| Vol 12, No 2 (2016) | ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova, A. V. Rodionov | ||
| "... предсердий (ФП), перенесших острый коронарный синдром и/или чрескожные интервенционные вмешательства на ..." | ||
| Vol 17, No 4 (2021) | Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention | Abstract similar documents |
| A. V. Panov | ||
| "... therapy (TAT), selection of P2Y12 inhibitor, choice of oral anticoagulant to be combined with antiplatelet ..." | ||
| Vol 14, No 1 (2018) | OUTPATIENT REGISTRY OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION (PROFILE-IM): DATA ON PREHOSPITAL THERAPY IN COMPARISON WITH THE LIS-3 REGISTRY | Abstract similar documents |
| N. P. Kutishenko, E. P. Kalaydzhyan, D. P. Sichinava, V. A. Evdakov, S. Yu. Martsevich | ||
| "... , antiplatelet agents and anticoagulants before reference AMI in patients of both registers did not differ ..." | ||
| Vol 18, No 6 (2022) | Adherence to Visits to Medical Institutions and Quality of Therapy after Acute Coronary Syndrome (according to the LIS Registry 3) | Abstract similar documents |
| N. P. Zolotareva, A. V. Zagrebelny, M. L. Ginzburg, S. Yu. Martsevich, O. M. Drapkina | ||
| "... <0.001) and antiplatelets (90.9%, p=0.001). In both groups, committed and not committed to attending ..." | ||
| Vol 18, No 2 (2022) | Changes in Long-term Mortality in Patients with Myocardial Infarction History According to the LIS Luberetskiy registry | Abstract PDF (Eng) similar documents |
| S. Y. Martsevich, N. P. Zolotareva, A. V. Zagrebelnyy, M. L. Ginzburg, O. M. Drapkina | ||
| "... difference was noted. The LIS-3 study revealed more frequent referrals for antiplatelet agents (20% vs 16 ..." | ||
| Vol 4, No 3 (2008) | ANTITHROMBOTIC THERAPY AT PERCUTANEOUS CORONARY INTERVENTIONS | Abstract similar documents |
| V. A. Sulimov | ||
| "... Possibilities of modern antiplatelet and antithrombotic therapy at percutaneous coronary ..." | ||
| Vol 12, No 5 (2016) | Clinical and Laboratory Predictors of Major Adverse Cardiac Events in Patients with Ischemic Heart Disease Following Elective Percutaneous Coronary Intervention | Abstract similar documents |
| E. Z. Golukhova, M. V. Grigoryan, M. N. Ryabinina, N. I. Bulaeva | ||
| "... antiplatelet therapy with acetyl salicylic acid and clopidogrel. Numerous clinical characteristics ..." | ||
| Vol 15, No 3 (2019) | Study of the Association of V640L (rs6133) Polymorphism in the Platelet P-selectin Gene with Acetylsalicylic Acid Resistance in Patients after Coronary Bypass Surgery | Abstract similar documents |
| A. A. Kosinova, T. S. Mongush, M. D. Goncharov, T. N. Subbotina, K. S. Semashchenko, G. Y. Kochmareva, Yu. I. Grinshtein | ||
| "... were confirmed by coronary angiography. The antiplatelet therapy was stopped for at least 5 days before ..." | ||
| Vol 8, No 2 (2012): | РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ ОСТРОГО КОРОНАРНОГО СИНДРОМА БЕЗ СТОЙКОГО ПОДЪЕМА СЕГМЕНТА ST | Abstract similar documents |
| , , , , , , , , , , , , , , , , | ||
| Vol 11, No 4 (2015) | INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION | Abstract PDF (Eng) similar documents |
| K. B. Mirzaev, R. E. Kazakov, V. V. Smirnov, D. A. Andreev, D. A. Sychev | ||
| "... of clopidogrel’s active metabolite and, respectively, its antiplatelet effect. We sought to determine the impact ..." | ||
| Vol 14, No 6 (2018) | Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice | Abstract PDF (Eng) similar documents |
| K. G. Pereverzeva, S. S. Yakushin, A. E. Pripadcheva, N. P. Agaltsova | ||
| "... value had 71 (68.3%) patients, HAS-BLED≥3 – 33 (31.7%). Only one antiplatelet agent was prescribed to 4 ..." | ||
| Vol 5, No 3 (2009) | ANTIPLATELET DRUGS RESISTANCE IN PATIENTS WITH ISCHEMIC HEART DISEASE AND OBLITERATIVE ATHEROSCLEROSIS OF LOWER LIMB ARTERIES ASSOCIATED WITH DIABETES MELLITUS TYPE 2 | Abstract similar documents |
| E. V. Gorjacheva, A. E. Udovichenko, V. A. Sulimov, N. V. Lavrishcheva, M. A. Surikova, T. N. Gracheva | ||
| "... ,007 in G2). Conclusion. Resistance to antiplatelet drugs is observed more often in patients with DM2 ..." | ||
| Vol 3, No 4 (2007) | RESISTANCE TO ACETYLSALICYLIC ACID AND PREVALENCE OF THROMBOSIS IN PATIENTS WITH STABLE ANGINA | Abstract similar documents |
| N. F. Putchinyan, N. V. Furman, P. Ya. Dovgalevskyi | ||
| "... связана с большей частотой тромбоза установленных стентов или аорто-коронарных шунтов. Заключение ..." | ||
| Vol 15, No 4 (2019) | According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention | Abstract similar documents |
| Company Pfizer | ||
| "... неклапанной фибрилляции предсердий и острым коронарным синдромом и/или чрескожным коронарным вмешательством ..." | ||
| Vol 6, No 6 (2010) | COMPARISON OF ANTIPLATELET EFFICACY OF ORIGINAL AND GENERIC ENTEROSOLUBLE ACETYLSALICYLIC ACID IN PATIENTS WITH HIGH CARDIOVASCULAR RISK. SIMPLE BLIND CROSSED RANDOMIZED CONTROLLED STUDY (IKAR) | Abstract similar documents |
| S. Yu. Martsevich, S. N. Tolpygina, E. S. Boychenko, R. E. Dubinskaya, Yu. V. Lukina, V. P. Voronina | ||
| "... Aim. To compare the antiplatelet efficacy of the original and generic enterosoluble tableted ..." | ||
| Vol 9, No 5 (2013) | TREATMENT OF PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN REAL CLINICAL PRACTICE ACCORDING TO THE DATA FROM PROGNOZ IBS REGISTER (PART 2) | Abstract similar documents |
| S. N. Tolpygina, Yu. N. Polyanskaya, S. Yu. Martsevich | ||
| "... ПРОГНОЗ ИБС), у которых обнаружен стеноз хотя бы одной коронарной артерии ≥50%. Оценку качества ..." | ||
| Vol 5, No 6 (2009) | ACETYLSALICYLIC ACID IN LOW DOSES FOR SECONDARY PREVENTION OF CARDIO-VASCULAR COMPLICATIONS | Abstract similar documents |
| N. A. Dmitrieva, S. N. Tolpygina | ||
| Vol 7, No 5 (2011) | HIGH VERSUS STANDARD CLOPIDOGREL MAINTENANCE DOSE AFTER PERCUTANEOUS CORONARY INTERVENTION AND EFFECTS ON PLATELET INHIBITION, ENDOTHELIAL FUNCTION, AND INFLAMMATION. RESULTS OF THE ARMYDA-150 MG (ANTIPLATELET THERAPY FOR REDUCTION OF MYOCARDIAL DAMAGE DURING ANGIOPLASTY) RANDOMIZED STUDY | similar documents |
| G. Patti, D. Grieco, G. Dicuonzo, V. Pasceri, A. Nusca, G. Sciascio | ||
| "... чрескожное коронарное вмешательство (ЧКВ). Материал и методы. Через месяц после ЧКВ (Т-0) 50 больных были ..." | ||
| Vol 21, No 2 (2025) | Myocardial infarction and embolism: a rare combination associated with a poor prognosis (a clinical case) | Abstract similar documents |
| O. L. Lyakhovich, O. V. Filyushin, S. S. Yakushin | ||
| "... следует отметить выбранную тактику с первоначальным проведением первичного чрескожного коронарного ..." | ||
| Vol 18, No 3 (2022) | Study the Association of Nucleotide Polymorphisms in Platelet Receptor and Cytochrome P450 Genes with the Development of Resistance to Antiplatelet Drugs in Patients with Coronary Artery Disease | Abstract similar documents |
| K. S. Semashchenko, T. S. Mongush, A. A. Kosinova, T. N. Subbotina, Y. I. Grinshtein | ||
| "... genes with the development of resistance to antiplatelet drugs in CHD patients. Material and Methods ..." | ||
| Vol 6, No 1 (2010) | ANTITHROMBOTIC THERAPY AT AN ATRIAL FIBRILLATION: OLD PROBLEMS AND NEW SOLUTIONS | Abstract similar documents |
| M. Yu. Gilyarov, V. A. Sulimov | ||
| "... The problem of antiplatelet drug choice in patients with atrial fibrillation is discussed. Authors ..." | ||
| Vol 6, No 4 (2010) | CLOPIDOGREL PHARMACOGENETICS | Abstract similar documents |
| A. N. Meshkov | ||
| "... in atherosclerosis progression and thrombotic complications. That is why antiplatelet therapy is a necessary element ..." | ||
| Vol 12, No 5 (2016) | Features of the Hemostasis and Platelets Enzyme Activity in Patients with Different Sensitivity to Acetylsalicylic Acid by the Acute Coronary Syndrome | Abstract similar documents |
| I. Yu. Grinshtein, A. A. Savchenko, Yu. I. Grinshtein, M. M. Petrova | ||
| "... method in the first day of ACS before antiplatelet therapy and on day 10. Results. Increase ..." | ||
| Vol 16, No 1 (2020) | Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients | Abstract similar documents |
| A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin | ||
| "... factors in plasma and vessel wall. Antiplatelet drugs do not always provide the necessary antithrombotic ..." | ||
| Vol 7, No 1 (2011) | THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS | Abstract similar documents |
| O. V. Gaisenok | ||
| "... Current issues of atherothrombosis prevention and treatment optimization with antiplatelet therapy ..." | ||
| Vol 7, No 4 (2011) | ON THE 125TH ANNIVERSARY OF ACETYLSALICYLIC ACID | Abstract similar documents |
| I. N. Bokarev, L. V. Popova | ||
| "... is highlighted. ASA modes of action and its position among the modern antiplatelet agents are considered ..." | ||
| Vol 21, No 2 (2025) | Rhabdomyolysis as a rare severe complication of statin therapy: differential diagnosis in real clinical practice (a clinical case) | Abstract similar documents |
| A. V. Melekhov, S. V. Borisovskaya, N. S. Gavrilina, I. I. Gaponova, I. G. Nikitin, O. A. Ettinger | ||
| "... . The widespread use of high-intensity statin therapy, often accompanied by the simultaneous use of ticagrelor ..." | ||
| Vol 17, No 3 (2021) | Optimal Medical Therapy for Chronic Coronary Syndrome: Realities and Prospects | Abstract similar documents |
| P. A. Lebedev, I. K. Petrukhina, A. A. Garanin, E. V. Paranina | ||
| "... therapy (OMT) for each patient with CCS, based on long-term treatment with antiplatelet agents, statins ..." | ||
| Vol 13, No 1 (2017) | MONITORING OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE | Abstract similar documents |
| N. F. Puchinian, N. V. Furman, L. I. Malinova, P. V. Dolotovskaya | ||
| "... to obtain the necessary information on the issue of control of antiplatelet therapy. The review brings ..." | ||
| Vol 3, No 3 (2007) | RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE | Abstract similar documents |
| D. H. Aynetdinova, A. E. Udovichenko, V. A. Sulimov | ||
| "... to antiplatelet drugs. There are many methods to detect sensitivity to antiplatelet drugs, but they all have ..." | ||
| Vol 17, No 1 (2021) | Comparative Assessment of the Clinical Course, Drug Therapy and Outcomes in Myocardial Infarction without or with Obstructive Coronary Artery Disease | Abstract similar documents |
| O. A. Fomina, S. S. Yakushin | ||
| "... of double antiplatelet therapy: (99.0% vs 80.6% р< 0.01) in MIOCA patients. In the MINOCA group а more ..." | ||
| Vol 14, No 1 (2018) | NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| K. B. Mirzaev, O. D. Konova, E. A. Grishina, K. A. Ryzhikova, Zh. A. Sozaeva, D. A. Andreev, M. Y. Gilyarov, D. A. Sychev | ||
| "... Background. Carriership of CYP4F2*3 (rs2108622, Val433Met) allelic variant can affect antiplatelet ..." | ||
| Vol 5, No 3 (2009) | FREE-RADICAL OXIDATION ACTIVITY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITHOUT Q WAVE TREATED WITH EPROSARTAN OR ENALAPRIL ADDITIONALLY TO THE BASIC THERAPY | Abstract similar documents |
| O. G. Zaylobidinov, Yu. N. Ziyaev, N. K. Kamilova, A. S. Khalilov, B. F. Mukhamedova | ||
| "... daily). Basic therapy included anticoagulants, antiplatelets, beta-blockers, nitrates and statins ..." | ||
| Vol 16, No 2 (2020) | Risk Factors, Clinical Features of the Course of Myocardial Infarction and Treatment of Young Patients Based on Two Hospital Registries | Abstract similar documents |
| O. L. Barbarash, D. Yu. Sedykh, I. S. Bykova, V. V. Kashtalap, A. D. Erlich | ||
| "... that these patients were less likely to receive aspirin (p=0.015), dual antiplatelet therapy (p=0.003), angiotensin ..." | ||
| Vol 6, No 2 (2010) | THE MODERN ASPECTS OF CLOPIDOGREL USE | Abstract similar documents |
| E. N. Dankovtseva, D. A. Zateyshchikov | ||
| Vol 7, No 3 (2011) | STROKE PREVENTION IN INTERNIST PRACTICE | Abstract similar documents |
| D. A. Napalkov, A. V. Zhilenko | ||
| "... требованиями современных рекомендаций. Современная фармакотерапия включает антиагреганты или антикоагулянты ..." | ||
| Vol 8, No 6 (2012) | THE LIS STUDY (LYUBERTSY STUDY ON MORTALITY RATE IN PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION). EVALUATION OF DRUG THERAPY. PART 2. INFLUENCE OF PREVIOUS DRUG TREATMENT ON LONG-TERM LIFE PROGNOSIS | Abstract similar documents |
| S. Yu. Martsevich, M. L. Gynzburg, N. P. Kutishenko, A. D. Deev, V. P. Smirnov, L. U. Drozdova, E. V. Daniels, A. V. Fokina | ||
| "... reference AMI only a small number of the patients received the main drug groups (antiplatelet agents, β ..." | ||
| Vol 20, No 6 (2024) | Multivessel coronary artery stenting complicated by stent thrombosis in the setting of hereditary thrombophilia: a clinical case | Abstract similar documents |
| Z. M. Safiullina, E. M. Mezhonov, S. V. Viatchinina, Yu. A. Vyalkina, A. Kh. Sereshcheva | ||
| "... and the choice of antiplatelet and anticoagulant therapy options, especially given the limited time frame ..." | ||
| Vol 14, No 6 (2018) | Evaluation of Drug Therapy and Adherence to It in Patients after Acute Coronary Syndrome in Real Clinical Practice (Results of One Year Observation) | Abstract PDF (Eng) similar documents |
| L. A. Khaisheva, S. E. Glova, V. A. Suroedov, A. S. Samakaev, S. V. Shlyk | ||
| "... was maximal for ACE inhibitors/angiotensin receptor blockers (83.6%), dual antiplatelet therapy (79.9%) and β ..." | ||
| Vol 16, No 4 (2020) | Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events? | Abstract similar documents |
| O. L. Barbarash, V. V. Kashtalap, I. A. Shibanova | ||
| "... and the antiplatelet agent – acetylsalicylic acid, are highlighted on the basis of the results of clinical studies ..." | ||
| Vol 10, No 3 (2014) | THE CAPABILITIES OF A REGISTER AS A QUALITY CONTROL OF THE PHARMACOTHERAPY IN OUTPATIENTS AT HIGH RISK OF CARDIOVASCULAR COMPLICATIONS (THE "LIS-1" REGISTER) | Abstract similar documents |
| M. L. Ginzburg, S. Y. Martsevich, N. P. Kutishenko, Y. V. Lukina, A. D. Deev | ||
| "... receiving b-blockers, 35.3% - renin-angiotensin-aldosterone system (RAAS) inhibitors, 15.7% - antiplatelet ..." | ||
| Vol 13, No 2 (2017) | TREATMENT CHARACTERISTICS OF ACUTE CORONARY SYNDROME IN ELDERLY PATIENTS: PRACTICE OF N.I. PIROGOV CITY CLINICAL HOSPITAL №1 | Abstract similar documents |
| M. Yu. Gilyarov, M. O. Zheltoukhova, E. V. Konstantinova, M. D. Muksinova, L. S. Muradova, A. P. Nesterov, A. E. Udovichenko | ||
| "... antiplatelet therapy (DAT) was prescribed to elderly patients in clinical practice approximately in 70 ..." | ||
| Vol 16, No 1 (2020) | An Attempt to Accord the Quality of Therapy of Stable Coronary Heart Disease Patients with Current Clinical Guidelines (ALIGN study): Design and the First Results | Abstract similar documents |
| S. Yu. Martsevich, E. D. Zharkova, N. P. Kutishenko, Yu. V. Lukina, S. N. Tolpygina, V. P. Voronina, A. V. Zagrebelnyy | ||
| "... %) of patients, 47 (66.2%) patients took beta-blockers, antiplatelet agents were taken by 61 people ..." | ||
| Vol 7, No 6 (2011) | ANTI-INFLAMMATORY EFFECT OF CLOPIDOGREL IN ATHEROSCLEROSIS | Abstract similar documents |
| L. I. Buriachkovskaia, A. B. Sumarokov, I. A. Uchitel, E. M. Gupalo | ||
| Vol 10, No 6 (2014) | THE SIGNIFICANCE OF PLATELET FUNCTIONAL ACTIVITY TESTING IN THE PREVENTION OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS RECEIVING ANTIPLATELET THERAPY | Abstract similar documents |
| D. A. Andreev | ||
| "... complications in patients receiving antiplatelet therapy is presented. Indications for antiplatelet therapy ..." | ||
| Vol 19, No 2 (2023) | Coronary Microvascular Dysfunction: Epidemiology, Clinical Presentation, Diagnosis and Treatment | Abstract similar documents |
| E. L. Trisvetova | ||
| "... значимый стеноз коронарных артерий. В этих случаях как причину ишемической болезни сердца рассматривают ..." | ||
| Vol 14, No 2 (2018) | WHAT DO PATIENTS WITH ATRIAL FIBRILLATION KNOW ABOUT STROKE AND SYSTEMIC EMBOLISM PREVENTION? DATA OF THE PRIMA-TERRA REGISTRY | Abstract similar documents |
| R. М. Linchak, O. G. Kompaniyets, A. M. Nedbaykin | ||
| "... warfarin, 15% new oral anticoagulants (NOAC). The majority of patients received antiplatelet agents ..." | ||
| Vol 16, No 5 (2020) | Changes in Antithrombotic Therapy of Atrial Fibrillation in the Hospital in 2011-2012 and 2016-2017 (Pharmacoepidemiological Analysis) | Abstract similar documents |
| O. V. Reshetko, A. V. Sokolov, N. V. Furman, V. V. Agapov | ||
| "... DS2-VASc=0 in 2016-2017 antiplatelet therapy was prescribed in 100% at the hospital stage ..." | ||
| Vol 16, No 2 (2020) | Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev | ||
| "... the follow-up. Their number was comparable in individuals taking antiplatelet agents and direct oral ..." | ||
| Vol 14, No 6 (2018) | Availability and Affordability of Medicines for the Treatment of Cardiovascular Diseases in Pharmacies in Six Regions of the Russian Federation | Abstract PDF (Eng) similar documents |
| A. E. Imaeva, Yu. A. Balanova, A. V. Kontsevaya, A. V. Kapustina, D. V. Duplyakov, O. H. Malysheva, I. V. Osipova, T. A. Petrichko, G. I. Kropanin, R. A. Kasimov, D. A. Leon, M. McKee | ||
| "... pharmacies. Among antiplatelet agents, aspirin was available in most pharmacies, and clopidogrel was mostly ..." | ||
| Vol 17, No 6 (2021) | Prehospital Period in Patients with COVID-19: Cardiovascular Comorbidity and Pharmacotherapy During the First Epidemic Wave (Hospital Registry Data) | Abstract similar documents |
| S. Yu. Martsevich, M. M. Lukyanov, M. M. Pulin, N. P. Kutishenko, E. Yu. Andreenko, V. P. Voronina, V. A. Dindikova, N. A. Dmitrieva, A. V. Zagrebelnyy, O. V. Lerman, A. N. Makoveeva, E. Yu. Okshina, A. A. Smirnov, E. V. Kudryashov, I. V. Budaeva, E. S. Nikoshnova, O. E. Karpov, O. M. Drapkina | ||
| "... not receive antihypertensive therapy, a low proportion of patients receiving antiplatelet agents and statins ..." | ||
| Vol 9, No 5 (2013) | THE ROLE OF LIPOTROPIC THERAPY IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE BEFORE AND AFTER CORONARY REVASCULARIZATION | Abstract similar documents |
| R. N. Adzhiev, M. S. Safarova, M. V. Ezhov | ||
| "... по оценке роли статинов до и после коронарного шунтирования и стентирования в снижении риска как ..." | ||
| Vol 7, No 4 (2011) | VASCULAR BED PECULIAR PROPERTIES IN PATIENTS WITH ISCHEMIC HEART DISEASE AND ARTERIAL HYPERTENSION. ROLE OF ANTIPLATELET THERAPY | Abstract similar documents |
| L. A. Haisheva, S. V. Shlyk | ||
| "... of revealed disorders with antiplatelet agent — clopidogrel 75 mg/day. Material and methods. 40 patients ..." | ||
| Vol 9, No 1 (2013) | POSSIBILITIES OF CLINICAL LABORATORY EVALUATION OF ANTIPLATELET THERAPY EFFECTIVENESS IN PATIENTS WITH ISCHEMIC HEART DISEASE | Abstract similar documents |
| O. V. Sirotkina, A. B. Laskovets, A. S. Lipunova, L. B. Gaykovaya, S. A. Boldueva, T. V. Vavilova | ||
| "... and induced flow cytofluorometry during antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA ..." | ||
| Vol 4, No 1 (2008) | COMPARISON OF ANTIPLATELET EFFECT AND SAFETY OF ORIGINAL DRUG «ASPIRIN CARDIO» AND GENERIC«ACECARDOL» IN PATIENTS WITH ARTERIAL HYPERTENSION 1-2 GRADE | Abstract similar documents |
| N. A. Belolipetskiy, S. N. Tolpygina, O. А. Litinskaya, V. G. Belolipetskaya, S. Yu. Martsevich | ||
| "... Aim. To compare antiplatelet effect of two acetylsalicylic acid medicines, Acecardol ("Synthesis ..." | ||
| Vol 12, No 4 (2016) | The use of oral anticoagulants in patients with atrial fibrillation: cohort study data | Abstract similar documents |
| O. V. Gaisenok, A. S. Leonov | ||
| "... . Results. The rate of OAC use was 46.5% (warfarin – 22.4%, NOAC – 20.7%), antiplatelet agents use – 60 ..." | ||
| Vol 8, No 5 (2012) | THE LIS STUDY (LYUBERTSY STUDY OF MORTALITY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION). EVALUATION OF THE PHARMACOTHERAPY. PART 1. TREATMENT OF PATIENTS BEFORE MYOCARDIAL INFARCTION AND ITS INFLUENCE ON HOSPITAL MORTALITY RATE | Abstract similar documents |
| S. Y. Marcevich, M. L. Ginzburg, N. P. Kutishenko, A. D. Deev, V. P. Smirnov, L. Y. Drozdova, E. V. Danijel's, A. V. Fokina | ||
| "... -blockers, 35.3% — ACE inhibitors, 15.7% — antiplatelet drugs, 1.9% — statins. Reduction in the hospital ..." | ||
| Vol 17, No 3 (2021) | The Effect of Clinical Characteristics and Stent Parameters on Left Ventricular Mechanical Dyssynchrony | Abstract PDF (Eng) similar documents |
| S. Mostafa, O. Sanad, M. Shawky, M. Magdy, E. Elkeshk | ||
| "... левого желудочка после планового чрескожного коронарного вмешательства (ЧКВ) на передней межжелудочковой ..." | ||
| Vol 18, No 6 (2022) | Perioperative Management of Patients Receiving Antithrombotic Therapy in Schemes and Algorithms | Abstract similar documents |
| O. N. Dzhioeva, E. A. Rogozhkina, O. M. Drapkina | ||
| "... of antiplatelet and/or anticoagulant drugs is a complicating factor in invasive and surgical procedures ..." | ||
| Vol 6, No 2 (2010) | EFFICACY AND SAFETY OF ACIDUM ACETYLSALICYLICUM USAGE | Abstract similar documents |
| V. N. Drozdov, V. A. Kim | ||
| "... Data about efficacy and safety of acetylsalicylic acid usage as antiplatelet drug and for cancer ..." | ||
| Vol 16, No 3 (2020) | A Prospective, Initiative, Single-Center Open Post-Registration Comparative Study of Laboratory Efficacy of Various Forms of Acetylsalicylic Acid in a Cardioprotective Dose with Different Composition of Excipients: Results of the SFAIROS Study | Abstract similar documents |
| N. V. Lomakin, L. I. Buryachkovskaya, D. A. Zolin, V. I. Kazey | ||
| Vol 9, No 6 (2013) | THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | Abstract similar documents |
| A. V. Shulkin, E. N. Yakusheva, N. M. Popova | ||
| "... , in rational pharmacotherapy in cardiology was shown on the example of its substrates – digoxin, antiplatelet ..." | ||
| 1 - 100 of 403 Items | 1 2 3 4 5 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
